|
|
Issue
|
Alert me when new journal issues are available via  or via  |
|
|
| Neurotherapeutics |
| Volume 5, Issue 2, Pages 163-376 (April 2008) |
|
Search Within This Issue
|
| Movement Disorders
|
| Edited by Mahlon DeLong, Stewart Factor |
|
|
|
|
|
|
|
|
|
 =free full text
|
|
|
|
Editorial
|
|
Advanced Therapies for Movement Disorders in Neurotherapeutics
Mahlon R. Delong, Stewart A. Factor
page 163
Full Text |
Full-Text PDF (24 KB)
|
|
|
Symptomatic Approaches
|
|
Current Status of Symptomatic Medical Therapy in Parkinson’s Disease
Stewart A. Factor
pages 164-180
Abstract |
Full Text |
Full-Text PDF (207 KB)
|
|
Symptomatic Treatment of Huntington Disease
Octavian R. Adam, Joseph Jankovic
pages 181-197
Abstract |
Full Text |
Full-Text PDF (277 KB)
|
|
Experimental Therapeutics for Dystonia
H.A. Jinnah, Ellen J. Hess
pages 198-209
Abstract |
Full Text |
Full-Text PDF (1497 KB)
|
|
|
Neuroprotective Approaches
|
|
Protection Against Parkinson’s Disease Progression: Clinical Experience
Peter A. LeWitt, Danette C. Taylor
pages 210-225
Abstract |
Full Text |
Full-Text PDF (186 KB)
|
|
Neuroprotection for Huntington’s Disease: Ready, Set, Slow
Steven M. Hersch, H. Diana Rosas
pages 226-236
Abstract |
Full Text |
Full-Text PDF (141 KB)
|
|
|
Restorative Approaches
|
|
|
Cellular Therapies for Parkinson's Disease
|
|
Therapeutic Potentials of Human Embryonic Stem Cells in Parkinson’s Disease
Mary B. Newman, Roy A.E. Bakay
pages 237-251
Abstract |
Full Text |
Full-Text PDF (216 KB)
|
|
Spheramine for Treatment of Parkinson’s Disease
Natividad P. Stover, Ray L. Watts
pages 252-259
Abstract |
Full Text |
Full-Text PDF (245 KB)
|
|
|
Gene Therapy
|
|
Advances in Gene Therapy for Movement Disorders
Hideki Mochizuki, Toru Yasuda, M. Maral Mouradian
pages 260-269
Abstract |
Full Text |
Full-Text PDF (377 KB)
|
|
|
Trophic Factors in Parkinson's Disease
|
|
Treatment of Parkinson’s Disease with Trophic Factors
Amie L. Peterson, John G. Nutt
pages 270-280
Abstract |
Full Text |
Full-Text PDF (146 KB)
|
|
|
Ablative Procedures
|
|
What Happened to Posteroventral Pallidotomy for Parkinson’s Disease and Dystonia?
Robert E. Gross
pages 281-293
Abstract |
Full Text |
Full-Text PDF (172 KB)
|
|
|
Deep Brain Stimulation
|
|
Mechanisms and Targets of Deep Brain Stimulation in Movement Disorders
Matthew D. Johnson, Svjetlana Miocinovic, Cameron C. McIntyre, Jerrold L. Vitek
pages 294-308
Abstract |
Full Text |
Full-Text PDF (408 KB)
|
|
Deep Brain Stimulation for Parkinson’s Disease
Patricia Limousin, Irene Martinez-Torres
pages 309-319
Abstract |
Full Text |
Full-Text PDF (471 KB)
|
|
Treatment of Dystonia with Deep Brain Stimulation
Jill L. Ostrem, Philip A. Starr
pages 320-330
Abstract |
Full Text |
Full-Text PDF (287 KB)
|
|
Deep Brain Stimulation and Tremor
Kelly E. Lyons, Rajesh Pahwa
pages 331-338
Abstract |
Full Text |
Full-Text PDF (98 KB)
|
|
Deep Brain Stimulation in Tourette’s Syndrome
Linda Ackermans, Yasin Temel, Veerle Visser-Vandewalle
pages 339-344
Abstract |
Full Text |
Full-Text PDF (93 KB)
|
|
|
Noninvasive DBS
|
|
Noninvasive Brain Stimulation for Parkinson’s Disease and Dystonia
Allan D. Wu, Felipe Fregni, David K. Simon, Choi Deblieck, Alvaro Pascual-Leone
pages 345-361
Abstract |
Full Text |
Full-Text PDF (540 KB)
|
|
|
Huntington Study Group Abstracts
|
|
Poster viewing
page 362
Full-Text PDF (38 KB)
|
|
HD Unmet Clinical Research Needs: Perspective From the Pre-Manifest HD Population
Katharine Moser
page 362
Full-Text PDF (38 KB)
|
|
Subtle Motor Abnormalities in Pre-Manifest HD Are Associated With Gene Status, Probability of Disease Onset, and Striatal Atrophy
K.M. Biglan, C.A. Ross, D.R. Langbehn, E. Aylward, J.C. Stout, S. Queller, N. Carlozzi, K. Duff, L.J. Beglinger, J.S. Paulsen, PREDICT-HD Investigators of the Huntington Study Group
page 362
Full Text |
Full-Text PDF (38 KB)
|
|
Optimal Measurement of Clinical and Biological Markers for Clinical Trials: The HD Toolkit Project
J.C. Stout, A. Tomusk, S. Queller, S. Lifer, S. Hastings, J. Dawson, B. Walker, K. Whitlock, S. Johnson
pages 362-363
Full Text |
Full-Text PDF (45 KB)
|
|
Break and poster viewing
page 363
Full-Text PDF (38 KB)
|
|
Emerging Clinical Candidates From the CHDI Pipeline
Robert Pacifici
page 363
Full-Text PDF (37 KB)
|
|
PHEND-HD: A Safety, Tolerability, and Biomarker Study of Phenylbutyrate in Symptomatic HD
S. Hersch, Huntington Study Group PHEND Investigators
page 363
Full Text |
Full-Text PDF (38 KB)
|
|
A Randomized, Controlled Trial of Ethyl-EPA for the Treatment of Huntington Disease: 12-Month Results
E.R. Dorsey, Huntington Study Group TREND-HD Investigators
page 363
Full Text |
Full-Text PDF (38 KB)
|
|
Experimental Therapeutics for Huntington’s Disease: Challenges and Hurdles to Successful Clinical Development
Russell Katz
page 363
Full-Text PDF (38 KB)
|
|
Abstract withdrawn
page 364
Full-Text PDF (40 KB)
|
|
First Report of Huntington’s Disease in West Asian Immigrants Living in the United States
T. Tempkin, V. Wheelock
page 364
Full Text |
Full-Text PDF (40 KB)
|
|
SCA2 Mimicking Juvenile Onset HD: A Case Report
G. Schwartz, J. Corey-Bloom, P. Mattis, A. Feigin
page 364
Full Text |
Full-Text PDF (40 KB)
|
|
Long-Term Treatment with Olanzapine and Risperidone in Relation to Dystonia in Huntington’s Disease
P. Young, D.L. McArthur, S. Perlman
pages 364-365
Full Text |
Full-Text PDF (50 KB)
|
|
Long-Term Effects of Olanzapine on Motor Features and Weight in Huntington’s Disease
V. Wheelock, T. Tempkin, S. Perlman, C. Higginson, L. Carr, K. Sigvardt
page 365
Full Text |
Full-Text PDF (42 KB)
|
|
COHORT: A Snapshot of Baseline Characteristics
M.C. Chirieac, A. Shinaman, I. Shoulson, Huntington Study Group CoHort Investigators
page 365
Full Text |
Full-Text PDF (42 KB)
|
|
Predictive Value of CAG Repeat Length for HD Onset: Effects of Ethnicity, Demographic, and Clinical Variables
A.E. Kane, G.M. Peavy, J.L. Goldstein, M.W. Jacobson, S. Lessig, L. Wasserman, J. Corey-Bloom
pages 365-366
Full Text |
Full-Text PDF (51 KB)
|
|
Five Years of Monitoring the Safety and Feasibility of PHAROS (Prospective Huntington At Risk Observational Study)
E.P. Kayson, Huntington Study Group PHAROS Investigators
page 366
Full Text |
Full-Text PDF (41 KB)
|
|
Brain Correlates of Neuropsychological Function in Presymptomatic HD Gene Carriers
P. Mattis, C. Tang, D. Zgaljardic, Y. Ma, V. Dhawan, M. Guttman, J.S. Paulsen, D. Eidelberg, A. Feigin
page 366
Full Text |
Full-Text PDF (41 KB)
|
|
Correction of Brain Atrophy in Metabolic Imaging of Presymptomatic Huntington’s Disease: A Combined FDG PET and MRI Study
Y. Ma, A. Feigin, S. Peng, P. Kingsley, V. Dhawan, D. Eidelberg
pages 366-367
Full Text |
Full-Text PDF (52 KB)
|
|
Plasma 8-OH2′dG As a Diagnostic and Pharmacodynamic Biomarker for HD
S. Hersch, H.D. Rosas, S. Gevorkian, D. Oakes, W. Matson
page 367
Full Text |
Full-Text PDF (42 KB)
|
|
HD Repeat Determines the Rate of Neuropathological Change
T. Massood, J. Latourelle, J. Srinidhi Mysore, E. Fossale, T. Gillis, J.F. Gusella, M.E. MacDonald, R.H. Myers
page 367
Full Text |
Full-Text PDF (42 KB)
|
|
A Study in Pre-Manifest Huntington’s Disease of Coenzyme Q10 (Ubiquinone)
K.M. Biglan, C.A. Ross
pages 367-368
Full Text |
Full-Text PDF (51 KB)
|
|
Recruitment and Retention Strategies for PREDICT-HD Study at HSG Site 144
O. Yastrubetskaya, J. Preston, E. Chiu
page 368
Full Text |
Full-Text PDF (41 KB)
|
|
PREDICT-HD Family Participation in HSG Site 144
O. Yastrubetskaya, A. Goh, J. Preston, E. Chiu
page 368
Full Text |
Full-Text PDF (41 KB)
|
|
Influence of Insurance on the Decision to Pursue Genetic Testing in Individuals at Risk for Huntington’s Disease
E. Oster, E.R. Dorsey, J. Bausch, A. Shinaman, E. Kayson, D. Oakes, I. Shoulson, K. Quaid, Huntington Study Group PHAROS Investigators
page 368
Full Text |
Full-Text PDF (41 KB)
|
|
Living at Risk: Concealing Risk and Preserving Hope in Huntington’s Disease
K. Quaid, S. Sims, M. Swenson, J. Harrison, C. Moskowitz, N. Stepanov, G. Suter, B. Westphal, Huntington Study Group PHAROS Investigators
pages 368-369
Full Text |
Full-Text PDF (50 KB)
|
|
Sensitivity of the UHDRS Cognitive Tests in Pre-Diagnosis and Early Huntington’s Disease (HD)
A. Tomusk, S. Queller, S. Lifer, S. Hastings, J. Dawson, B. Walker, K. Whitlock, J.C. Stout
page 369
Full Text |
Full-Text PDF (41 KB)
|
|
Longitudinal Decline in Negative Emotion Recognition Prior to Diagnosis in Huntington’s Disease
S.A. Johnson, J.C. Stout, S. Queller, K. Whitlock, D. Langbehn, E. Aylward, J. Paulsen, PREDICT-HD Investigators of the Huntington Study Group
page 369
Full Text |
Full-Text PDF (41 KB)
|
|
Abnormal Structure of Cerebral White and Cortical Gray Matter in Preclinical Huntington’s Disease
P. Nopoulos, J. Paulsen, L. Beglinger, H. Johnson, V. Magnotta, R. Pierson, D. Langbehn, PREDICT-HD Investigators and Coordinators of the Huntington Study Group
pages 369-370
Full Text |
Full-Text PDF (50 KB)
|
|
Late-Onset Huntington’s Disease: A Review of 41 Cases
H. Lipe, T.D. Bird
page 370
Full Text |
Full-Text PDF (40 KB)
|
|
Huntington’s Disease: Causes and Place of Death in a Closely Followed Population
E.A. McCusker, A. Lownie
page 370
Full Text |
Full-Text PDF (40 KB)
|
|
How People With Huntington’s Disease Die: A Survey
A.J. Lechich, S. Montas, A. Duckett, C. Moskowitz, J. Klager, S. Sandler, A. Pae
page 370
Full Text |
Full-Text PDF (40 KB)
|
|
The MLK Inhibitor, CEP-1347, Suppresses Mutant Huntingtin-Associated Neurotoxicity in Cell, Drosophila and Mouse Models of HD by Modulating MAPK Signaling and Upregulating Brain Derived Neurotrophic Factor
B.L. Apostol, D.A. Simmons, C. Zuccato, K. Illes, J. Pallos, M. Casale, S. Kathuria, E. Cattaneo, J.L. Marsh, L. Michels Thompson
page 371
Full Text |
Full-Text PDF (44 KB)
|
|
Discovery and Development of Novel HDAC Inhibitors for Huntington’s Disease
H. Patzke, R. Chesworth, Z. Li, G. Rahil, J. Wang, J. Smith, F.L. Huet, G. Shapiro, S. Leit, P. Beaulieu, F. Raeppel, M. Fournel, H. Sainte-Croix, S.J. Nolan, F.P. Albayya, A. Barbier, J. Besterman, M.K. Ahlijanian, R. Deziel
page 371
Full Text |
Full-Text PDF (44 KB)
|
|
A Scale To Measure Quality of Life in Huntington’s Disease Spousal Carers
A. Aubeeluck, H. Buchanan
page 371
Full Text |
Full-Text PDF (44 KB)
|
|
A Model of the Extent and Impact of Inter-Rater Variability for the UHDRS Motor and Diagnostic Confidence Scales
D.R. Langbehn, J.S. Paulsen, C. Ross, K. Biglan, B. Landwehrmeyer
page 372
Full Text |
Full-Text PDF (42 KB)
|
|
Item Reduction of the University of Pennsylvania Smell Identification Test: Preparation for Clinical Trials in Pre-HD using the PREDICT-HD Cohort
K.B. Whitlock, J.C. Stout, S. Queller, D.R. Langbehn, N.E. Carlozzi, J.S. Paulsen, PREDICT-HD Investigators of the Huntington Study Group
page 372
Full Text |
Full-Text PDF (42 KB)
|
|
Candidates for Neurocognitive Markers in PRE-HD: Longitudinal Assessment From the PREDICT-HD COHORT
J.C. Stout, N.E. Carlozzi, S. Queller, K.B. Whitlock, S.A. Johnson, D.R. Langbehn, L.J. Beglinger, K. Duff, J.S. Paulsen, PREDICT-HD Investigators of the Huntington Study Group
page 372
Full Text |
Full-Text PDF (42 KB)
|
|
Proposed Criteria for the Diagnosis of Dementia Associated With Huntington’s Disease (HD)
G.M. Peavy, M.W. Jacobson, A.E. Kane, J.L. Goldstein, L. Mickes, S. Lessig, J. Lee, J. Corey-Bloom
page 373
Full Text |
Full-Text PDF (43 KB)
|
|
Controlling for Individual Differences in Neurocognitive Markers in Pre-Diagnosis HD in the PREDICT-HD Cohort
J.C. Stout, S. Queller, K.B. Whitlock, N.E. Carlozzi, D.R. Langbehn, J.S. Paulsen, PREDICT-HD Investigators of the Huntington Study Group
page 373
Full Text |
Full-Text PDF (43 KB)
|
|
A Comparison of Two Brief Cognitive Screening Instruments in Huntington Disease (HD)
L. Mickes, A.E. Kane, M.W. Jacobson, G.M. Peavy, J.L. Goldstein, S. Lessig, R.Y. Kim, B. Di Toro, E. Fine, J. Corey-Bloom
page 373
Full Text |
Full-Text PDF (43 KB)
|
|
Genetic Testing for the Huntingtin Gene CAG Repeat Comparing DNA from Buccal Swabs with DNA from Peripheral Blood
L. Wasserman, T. Cahill, D. Johnson, J. Goldstein, G. Peavy, M. Jacobson, J. Corey-Bloom
page 374
Full Text |
Full-Text PDF (41 KB)
|
|
Treatment of HD: A Survey of HD Clinicians
L. Veatch Goodman, P.G. Como, J.H. Cha, J.S. Paulsen
page 374
Full Text |
Full-Text PDF (41 KB)
|
|
|
|
|
|
|
|
